Hormonal
Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.
For patients with obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide (15 mg weekly) has been shown to significantly reduce the risk of heart failure hospitalizations and cardiovascular death. It also improves heart structure and quality of life. This makes it a valuable option for this specific population, in addition to its benefits for diabetes and weight loss.
The primary endpoint (a composite of cardiovascular death or heart failure hospitalization) was significantly reduced: 9.9% of tirzepatide patients vs 15.3% of placebo patients had an event. This ~38% relative risk reduction was mostly driven by fewer heart failure hospitalizations (8.0% vs 14.2%).
Why this rating
Based on the SUMMIT trial (Phase 3 RCT), but long-term mortality data is still pending (SURPASS-CVOT).
Source
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Mrudula Thiriveedi et al. · Annals of Medicine and Surgery · 2025
DOI 10.1097/ms9.0000000000004055
More from this paper
- Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.Strong
- Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →